Compare Nuscale Power Corporation (SMR) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuscale Power Corporation vs Smith & Nephew plc — how do they compare? Nuscale Power Corporation trades at $7.11 (market cap $3.00B), while Smith & Nephew plc trades at $27.14 (market cap $11.10B). The key difference: Smith & Nephew plc is far larger — about 3.7× Nuscale Power Corporation's market cap, and Smith & Nephew plc pays a 2.95% dividend while Nuscale Power Corporation pays none. Which is the better fit depends on your goals.
| SMR | SNN | |
|---|---|---|
Market Cap | $3.00B | $11.10B |
Volume | 43,143,109 | 1,051,703 |
Sector | Industrials | Health |
52-Week High | $53.43 | $37.17 |
52-Week Low | $7.32 | $26.42 |
Enterprise Value | $1.93B | $14.13B |
Typical Hold Time | — | 121 Days |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SMR stock trades at $7.23, down 5.74% on the day, reflecting a bearish technical trend and weak financial performance. The company reported a net loss of $355.79 million in 2025 on revenue of $31.48 million, with a negative net income margin of -3,888.7%. Despite analyst consensus pointing to a $11.25 price target, recent news highlights an ongoing SEC investigation and intense competition in the small modular reactor market.
The outlook remains highly speculative, with significant execution risk and cash burn offsetting long-term potential in the nuclear energy sector. While institutional interest and a 50% buy rating suggest some optimism, the stock's high volatility and lack of profitability present substantial risks for investors.
SNN trades at $27.10, near its 52-week low, with a bearish technical signal. The company reported solid fundamentals with revenue growth to $6.16B in 2025 and a net income margin of 10.08%. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio. Cash flow from operations remains strong at $1.29B, though net cash flow was negative $64M in 2025.
The outlook is mixed: strong profitability and innovation support long-term value, but near-term headwinds include analyst downgrades and competitive pressures. Risks involve execution challenges and market sentiment. The stock presents a cautious opportunity for value investors, balancing solid fundamentals against current bearish trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuscale Power Corporation
NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.
Read more on SMR →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
